$IAUX

i-80 Gold Corp. (IAUX): Results of Operations and Financial Condition

i-80 Gold Corp. (IAUX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 i-80goldcorppressreleaseq2.htm EX-99.1 Document i-80 Gold Reports Second Quarter 2026 Results; On Track to Achieve Full-Year Guidance as Granite Creek Ramps Up and Development Plan Advances TORONTO, ON, August 10 , 2 026 – i-80 GOLD CORP. (NYSE:IAUX) (TSX:IAU) (“i-80 Go

Original reporting
Published Aug 10, 2026, 9:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$IAUX
Bullish
medium confidence
Mentioned
$IAUX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IAUXBullishMed
01

Why it matters

Traders can update near-term expectations for feasibility-study timing (Q3 2026) and first-gold milestones (Q4 2026 for Archimedes mining and Lone Tree construction start), while reassessing cash burn and execution risk from the disclosed operating results and project progress.

02

Market read

A development-stage gold producer’s quarterly execution update with concrete milestone timing and updated financial/cash metrics can reprice probability-weighted outcomes into Q3-Q4 catalysts.

03

What to watch

Revenue fell due to third-party processing delays, and the filing notes strategy changes that could raise Archimedes expenditures, both of which can pressure future cash needs.

Relevance 7/10Novelty 7/10Timing: after-hours filing today, with Q3 2026 feasibility study and Q4 2026 first-gold milestones flagged

Background

This is an SEC Form 8-K with Item 2.02, attaching a press release covering i-80 Gold’s Q2 2026 financials and development highlights across Granite Creek, Archimedes, and Lone Tree Plant refurbishment.

Company-level read

Ticker impact

$IAUXBullishMedium confidence
Context

i-80 Gold reports Q2 2026 results and says Granite Creek ramp-up, Archimedes progress, and Lone Tree demolition are on track for 2026 milestones.

Expected impact

Moderately positive bias, with potential volatility around follow-through on Q4 2026 milestones and the Q3 2026 feasibility-study timing.

Evidence & confidence

Revenues, production, gross profit, cash burn, and project execution updates are all newly disclosed in an 8-K, but the article does not include a new guidance number or a surprise event beyond execution commentary.

Market effects

Adds incremental datapoints for Nevada-focused mid-tier gold development timelines and execution risk, relevant to small-cap gold sentiment.

Highlights Northern Nevada project progress and permitting status, which can influence local development-risk perception.

Limited direct global impact; primarily company-specific for a development-stage producer.

Counterpoint

Despite higher production and gross profit, the company’s net loss and cash used in operations remain large, so equity risk may still dominate even if milestones are “on track.”

Key entities

  • i-80 Gold Corp.

    Reports Q2 2026 results, production increase, cash position, and development milestones for Granite Creek, Archimedes, and Lone Tree Plant.

  • Granite Creek

    Underground development ramp-up ahead of plan; feasibility study anticipated in Q3 2026.

  • Archimedes

    Underground advancement on schedule and largely on budget; ventilation raise in preparation for first gold by year-end 2026.

  • Lone Tree Plant

    Refurbishment demolition commenced mid-June; major construction targeted for Q4 2026.

Related articles

$RKLBMedAI 8/10

Rocket Lab reports record quarter amid Iridium takeover bid

Rocket Lab reported record Q2 revenue of $234m, up 62% year over year, but a net loss of $49m versus $66m a year earlier. It said order backlog reached just under $2.4bn. The company expects current-quarter revenue of $250m to $265m and is pursuing an Iridium acquisition to expand into communications. Shares fell about 3% after hours.

$QDELHighAI 9/10

Why QuidelOrtho (QDEL) Stock Is Nosediving

QuidelOrtho (QDEL) shares fell 21.3% after the company cut its full-year revenue and adjusted EPS outlook despite a Q2 beat. Q2 revenue was $630.9M and adjusted EPS $0.13. Full-year guidance was lowered to $2.52B-$2.6B revenue and adjusted EPS of $0.65-$0.90, with the midpoint below analyst estimates.

$GRMNMed

Why Garmin Stock Soared in July and Is at an All-Time High

Garmin (GRMN) reported a strong second quarter and raised full-year revenue and EPS guidance, implying about 11% year-over-year revenue growth and nearly 17% EPS growth, according to the company. Shares rose 23.7% in July and are up 53% year to date, with advanced wearables driving fitness segment growth. The article cites S&P Global Market Intelligence.

$KEELMed

Why Keel Infrastructure Stock Dived by Over 12% Today

Keel Infrastructure (KEEL) reported Q2 results before the open. Revenue fell 50% year over year to $30 million, while operating expenses declined to just over $54 million. Net loss widened to about $65 million, or $0.11 per share. The stock dropped more than 12% on the day. Keel said its three AI data center sites are near full permitting and it is in talks with potential tenants.

$UTLMed

Unitil Q2 Earnings Call Highlights

Unitil (NYSE:UTL) reported first-half gas adjusted gross margin up 13.5% to $122.7 million, citing Maine Natural Gas and colder weather. It added about 6,600 gas customers, mainly from the Maine Natural Gas acquisition. Unitil closed a $55.8 million New Hampshire water deal, expects it neutral to EPS in 2026, and is pursuing rate cases and a $1.2 billion capital plan through 2030.

$BHCMedAI 8/10

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.